The Full Wiki

More info on PRX-07034

PRX-07034: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

PRX-07034
Systematic (IUPAC) name
N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
Identifiers
CAS number ?
ATC code none
PubChem 11532574
Chemical data
Formula C21H29Cl2N3O4S 
Mol. mass 490.44 g/mol
SMILES eMolecules & PubChem
Therapeutic considerations
Pregnancy cat.  ?
Legal status Uncontrolled
Routes Oral

PRX-07034 is a selective 5-HT6 receptor antagonist.[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.[2][3][1][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][7][6]

References

  1. ^ Fone KC (November 2008). "An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function". Neuropharmacology 55 (6): 1015–22. doi:10.1016/j.neuropharm.2008.06.061. PMID 18655798. http://linkinghub.elsevier.com/retrieve/pii/S0028-3908(08)00241-4. 
  2. ^ Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity". Drugs 67 (1): 27–55. PMID 17209663. http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27. 
  3. ^ "PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials". http://investorshub.advfn.com/boards/read_msg.aspx?message_id=11491017. 
  4. ^ a b "Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009". http://blog.taragana.com/pr/epix-pharmaceuticals-inc-announces-a-successful-auction-sale-of-five-drug-program-intellectual-properties-on-september-30-2009-6816/. 
  5. ^ "Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction". http://blog.taragana.com/pr/epix-pharmaceuticals-inc-announces-prx-07034-therapeutics-cns-phase-2-will-be-part-of-the-intellectual-property-offered-for-sale-at-the-september-30-2009-auction-4809/. 

External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message